Adjacent Level Anterior Cervical Fusion: SeaSpine Shoreline Versus Removal of Previously Implanted Plate and Replating
Launched by RESEARCH SOURCE · May 10, 2024
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a retrospective, prospective, post-market, observational, single-center, single surgeon study evaluating the use of the SeaSpine Shoreline device. Patients will be identified by the Investigator as needing, or already received the device during a cervical fusion surgery and meeting all the inclusion and none of the exclusion criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Appropriate patient, as determined by the Investigator, scheduled for an elective cervical spine fusion to treat adjacent level cervical disc herniation or degeneration resulting in cervical radiculopathy or myelopathy
- • 2. At least 18 years of age
- • 3. Failure of nonoperative care
- • 4. Previous anterior cervical plating
- • 5. Psychosocially, mentally and physically able to comply with this protocol including adhering to follow-up schedule and study requirements
- Exclusion Criteria:
- • 1. Pregnancy or anticipated to become pregnant during the course of the study
- • 2. No previous cervical spine surgery
- • 3. Non-instrumented cervical fusion
- • 4. Cervical fusion with separate plate fixation
- • 5. Unwilling or unable to sign consent
- • 6. Patient has any condition, that in the opinion of the Investigator, would prohibit the patient from complying with the protocol
- • 7. Currently a prisoner
About Research Source
Research Source is a leading clinical trial sponsor dedicated to advancing medical science through innovative research and development. With a focus on delivering high-quality, evidence-based solutions, Research Source collaborates with a diverse network of healthcare professionals, institutions, and industry partners to conduct rigorous clinical studies across various therapeutic areas. Committed to ethical standards and patient safety, the organization strives to accelerate the discovery of new treatments and improve patient outcomes while ensuring compliance with regulatory requirements. Through its expertise and strategic approach, Research Source aims to contribute significantly to the future of healthcare and the well-being of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Southfield, Michigan, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported